




In the US generics now command ~55% share of total prescription volume; More than 90% of Aricept Rx has shifted to generic donepezil since November 2010; Namenda and Exelon patch, respectively maintain relatively stagnant ~33% and ~8.5% shares.

US Alzheimer's Prescription Share (TRx)

Updated: 02/15/12



	Share	Share Change (% points)			CAGR		
		Dec-11	1MR	3MR	12MR	QTD	YTD
<b>Total TRx</b>						<b>0.2%</b>	<b>0.4%</b>
<b>AChE Inhibitor</b>	<b>66.8%</b>		<b>0.3</b>	<b>0.5</b>	<b>0.0</b>	<b>0.9%</b>	<b>0.4%</b>
Aricept	3.1%		-18.4	-38.4	-44.6	-92.3%	-89.9%
Donepezil	50.1%		19.6	39.6	45.1	386.8%	1765.4%
Exelon	0.1%		-0.4	-0.4	-1.5	-74.4%	-86.0%
Exelon Patch	8.4%		0.2	0.2	0.4	2.4%	4.8%
Rivastigmine	2.0%		0.0	0.1	1.2	3.7%	134.3%
Razadyne	0.1%		-0.1	-0.1	-0.1	-52.4%	-56.2%
Galantamine	3.0%		-0.5	-0.5	-0.4	-14.5%	-9.7%
<b>NMDA Antagonist</b>	<b>33.2%</b>		<b>-0.3</b>	<b>-0.5</b>	<b>0.0</b>	<b>-1.2%</b>	<b>0.5%</b>
Namenda	33.2%		-0.3	-0.5	0.0	-1.2%	0.5%



Notes: Prescription includes both branded and generic products; Share Change compares the share for 12/11 vs. 1 month, 3 months, and 12 months ago; YTD growth compares TRx for 2011 vs. the TRx for 2010; QTD growth compares TRx for the 3months 10/11-12/11 vs. the 3 months 10/10-12/10; MTD compares TRx for the month 12/11 vs. the month 12/10; Sources: SDI (IMS) retail sales and prescription data